Trial · NCT03417102
Results by group26
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 26
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Estimated Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy Period | Bypassing Agents (BPA) On-demand | 18.071 | 95% Confidence Interval 10.598 to 30.812 | episodes per participant per year | |
| Estimated Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy Period | Fitusiran 80 mg Prophylaxis | 1.666 | 95% Confidence Interval 1.014 to 2.736 | episodes per participant per year | |
| Observed Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy Period | Bypassing Agents (BPA) On-demand | 18.1 | Standard Deviation 14.9 | episodes per participant per year | |
| Observed Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy Period | Fitusiran 80 mg Prophylaxis | 1.7 | Standard Deviation 3.8 | episodes per participant per year | |
| Estimated Annualized Bleeding Rate (ABR) for Treated Bleeds During the Treatment Period | Bypassing Agents (BPA) On-demand | 18.819 | 95% Confidence Interval 11.541 to 30.687 | episodes per participant per year | |
| Estimated Annualized Bleeding Rate (ABR) for Treated Bleeds During the Treatment Period | Fitusiran 80 mg Prophylaxis | 2.024 | 95% Confidence Interval 1.306 to 3.138 | episodes per participant per year | |
| Observed Annualized Bleeding Rate (ABR) for Treated Bleeds During the Treatment Period | Bypassing Agents (BPA) On-demand | 18.8 | Standard Deviation 15.4 | episodes per participant per year | |
| Observed Annualized Bleeding Rate (ABR) for Treated Bleeds During the Treatment Period | Fitusiran 80 mg Prophylaxis | 2.0 | Standard Deviation 3.7 | episodes per participant per year | |
| Estimated Annualized Spontaneous Bleeding Rate for Treated Bleeds During Efficacy Period | Bypassing Agents (BPA) On-demand | 15.675 | 95% Confidence Interval 9.281 to 26.471 | episodes per participant per year | |
| Estimated Annualized Spontaneous Bleeding Rate for Treated Bleeds During Efficacy Period | Fitusiran 80 mg Prophylaxis | 0.872 | 95% Confidence Interval 0.491 to 1.551 | episodes per participant per year | |
| Observed Annualized Spontaneous Bleeding Rate for Treated Bleeds During the Efficacy Period | Bypassing Agents (BPA) On-demand | 15.6 | Standard Deviation 14.9 | episodes per participant per year | |
| Observed Annualized Spontaneous Bleeding Rate for Treated Bleeds During the Efficacy Period | Fitusiran 80 mg Prophylaxis | 0.9 | Standard Deviation 2.0 | episodes per participant per year | |
| Estimated Annualized Joint Bleeding Rate for Treated Bleeds During the Efficacy Period | Bypassing Agents (BPA) On-demand | 13.759 | 95% Confidence Interval 7.950 to 23.811 | episodes per participant per year | |
| Estimated Annualized Joint Bleeding Rate for Treated Bleeds During the Efficacy Period | Fitusiran 80 mg Prophylaxis | 1.349 | 95% Confidence Interval 0.798 to 2.280 | episodes per participant per year | |
| Observed Annualized Joint Bleeding Rate for Treated Bleeds During the Efficacy Period | Bypassing Agents (BPA) On-demand | 13.8 | Standard Deviation 12.2 | episodes per participant per year | |
| Observed Annualized Joint Bleeding Rate for Treated Bleeds During the Efficacy Period | Fitusiran 80 mg Prophylaxis | 1.4 | Standard Deviation 3.4 | episodes per participant per year | |
| Health-related Quality of Life (HRQOL): Change From Baseline in Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QOL) Physical Health Domain Score at Month 9 | Bypassing Agents (BPA) On-demand | -1.94 | 95% Confidence Interval -10.32 to 6.43 | score on a scale | |
| Health-related Quality of Life (HRQOL): Change From Baseline in Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QOL) Physical Health Domain Score at Month 9 | Fitusiran 80 mg Prophylaxis | -30.67 | 95% Confidence Interval -36.90 to -24.43 | score on a scale | |
| Health-related Quality of Life (HRQOL): Change From Baseline in Haem-A-QOL Total Score at Month 9 | Bypassing Agents (BPA) On-demand | -0.42 | 95% Confidence Interval -5.65 to 4.80 | score on a scale | |
| Health-related Quality of Life (HRQOL): Change From Baseline in Haem-A-QOL Total Score at Month 9 | Fitusiran 80 mg Prophylaxis | -15.27 | 95% Confidence Interval -19.30 to -11.24 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03417102/results